Skip to main content
HUBEI GUANGJI PHARMACEUTICAL CO., LTD logo

HUBEI GUANGJI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 000952 ISIN · CNE0000010R5 LEI · 3003000UBR6337H70Q25 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,073 across all filing types
Latest filing 2026-05-25 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000952

About HUBEI GUANGJI PHARMACEUTICAL CO., LTD

https://www.guangjipharm.com

HUBEI GUANGJI PHARMACEUTICAL CO., LTD. focuses on the research, development, and large-scale manufacturing of pharmaceutical raw materials and finished medicinal products. The company is a prominent global supplier of Vitamin B2 (Riboflavin), leveraging specialized fermentation processes to serve international markets. Its extensive product catalog includes Vitamin B6, various pharmaceutical intermediates, and finished dosage forms such as tablets, capsules, and injections. The organization maintains integrated production facilities and research departments dedicated to biotechnological advancements and chemical synthesis. By adhering to international quality standards, the company provides essential components for the pharmaceutical, food fortification, and animal nutrition sectors worldwide.

Recent filings

Filing Released Lang Actions
关于回购注销限制性股票减少注册资本通知债权人公告
Transaction in Own Shares Classification · 88% confidence The document is an announcement by the board of Hubei Guangji Pharmaceutical Co., Ltd. notifying creditors of the repurchase and cancellation of restricted stock under its incentive plan, resulting in a reduction of registered capital. This is a corporate share repurchase transaction and capital change. It does not contain financial statements or investor presentation materials. Therefore, it fits the definition of Transaction in Own Shares (share buyback).
2026-05-25 Chinese
湖北众勤律师事务所关于湖北广济药业股份有限公司2025年年度股东会股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter by Zhong Qin Law Firm regarding the convening, attendance, voting procedures, and validity of the 2025 Annual General Meeting of Hubei Guangji Pharmaceutical Co., Ltd. It is not the actual annual report, earnings release, or investor presentation, nor is it a pure voting results announcement by the company; rather it is a lawyer’s certification of the AGM’s legality. There is no dedicated category for external legal opinions on shareholder meetings. Accordingly, this falls into the general “Regulatory Filings” (RNS) fallback category.
2026-05-22 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a formal announcement of the 2025 annual general meeting resolutions, detailing attendance, each proposal voted upon, and the vote counts (agree/oppose/abstain). This directly matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report" for the fiscal year 2025. It is issued by a certified accounting firm (利安达会计师事务所) and addresses the effectiveness of internal controls over financial reporting as of December 31, 2025. The content includes auditor responsibilities, company responsibilities, and an audit opinion on internal control effectiveness. The document is not a full annual report but a standalone audit report focused on internal control over financial reporting. It is not a brief announcement or certification letter but a formal audit report. Therefore, it fits the category of Audit Report / Information (AR). The document length is 2455 characters, which is reasonable for an audit report and not just a short announcement. Hence, the classification is AR with high confidence. FY 2025
2026-04-24 Chinese
浙江佰事诚律师事务所关于湖北广济药业股份有限公司回购注销2021年限制性股票激励计划剩余全部限制性股票之法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted stocks under a 2021 restricted stock incentive plan by 湖北广济药业股份有限公司. It details the legal compliance, approvals, authorizations, reasons, quantities, prices, and funding sources for the repurchase and cancellation of restricted shares. The document is not a financial report, earnings release, or management discussion but a legal opinion related to a share repurchase transaction. It is not a simple announcement but a detailed legal opinion letter. The content aligns best with a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares. The document length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is POS with high confidence.
2026-04-24 Chinese
第十一届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 17th meeting of the 11th Board of Directors of 湖北广济药业股份有限公司. It includes approvals of the 2025 Annual Report, 2025 Annual Board Work Report, 2025 General Manager Work Report, 2025 Financial Final Report, profit distribution plan, internal control self-evaluation report, remuneration proposals, ESG report, and other governance and financial matters. The document repeatedly states that the actual reports (e.g., 2025 Annual Report, 2025 Financial Final Report, ESG Report) are disclosed separately on designated media with specific announcement numbers. This document itself is a board meeting resolution announcement summarizing approvals and decisions, not the full annual report or financial statements. It is not a call transcript, earnings release, or other categories. The document is over 5,000 characters and contains substantive content about board decisions, but it does not contain the full financial data or detailed report content itself. Therefore, it is best classified as Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2026-04-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.